Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles
- PMID: 38040931
- DOI: 10.1007/s00259-023-06544-2
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles
Abstract
Purpose: Currently, the most used peptide receptor radionuclide therapy (PRRT) regimen for neuroendocrine tumors comprises 4 treatment cycles, and there is not enough large-scale data to support the safety of more individualized extended PRRT. This study aims to evaluate the therapeutic effectiveness and potential nephrotoxicity related to PRRT using more than four treatment cycles.
Methods: In this retrospective analysis, we included patients who had received at least four PRRT cycles and had available follow-up data. We analyzed renal function indicators before and after multiple treatments, comparing nephrotoxicity in patients receiving four cycles ("standard") with those receiving more than four ("extended treatment"). Nephrotoxicity was assessed via creatinine levels and CTCAE creatinine grades. Treatment effectiveness was gauged using Kaplan-Meier survival analysis, focusing on overall survival and disease-specific survival (DSS). Statistical analyses were performed using SPSS version 26 (IBM), R 4.2.3, and GraphPad Prism 9.0.0. Statistical significance was defined as a P-value of less than 0.05.
Results: Our study cohort consisted of 281 patients in the standard group and 356 in the extended treatment group. No significant differences in baseline characteristics or renal function were noted between the two groups pre-treatment. Mean post-treatment creatinine levels did not significantly differ between the standard (89.30 ± 51.19 μmol/L) and extended treatment groups (93.20 ± 55.98 μmol/L; P = 0.364). Similarly, there was no statistical significance between the CTCAE creatinine grades of the two groups (P = 0.448). Adverse renal events were observed in 0.4% of patients in the standard group and 1.1% in the extended treatment group. After a median follow-up time of 88.3 months, we found that median overall survival was significantly higher in the extended treatment group (72.8 months) compared to the standard treatment group (52.8 months). A Cox regression analysis further supported these findings, indicating a better prognosis for the extended treatment group in terms of overall survival (HR: 0.580, P < 0.001) and DSS (HR: 0.599, P < 0.001).
Conclusion: Our findings suggest that extending PRRT treatment beyond the standard four cycles may be a safe and effective therapeutic strategy for NET patients. This approach could be particularly beneficial for patients experiencing disease recurrence or progression following standard treatment.
Keywords: Nephrotoxicity; Neuroendocrine tumors (NETs); Peptide receptor radionuclide therapy (PRRT); Prognosis.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Long-term Nephrotoxicity after PRRT: Myth or Reality.Theranostics. 2024 Jan 1;14(2):451-459. doi: 10.7150/thno.92487. eCollection 2024. Theranostics. 2024. PMID: 38169589 Free PMC article.
-
177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.J Nucl Med Technol. 2016 Jun;44(2):65-9. doi: 10.2967/jnmt.115.168146. Epub 2016 Feb 4. J Nucl Med Technol. 2016. PMID: 26848166
-
Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):913-923. doi: 10.1007/s00259-020-05004-5. Epub 2020 Sep 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 32876706
-
The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.Neuroendocrinology. 2021;111(11):1086-1098. doi: 10.1159/000516015. Epub 2021 Mar 19. Neuroendocrinology. 2021. PMID: 33744879 Review.
-
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?Front Endocrinol (Lausanne). 2022 Oct 31;13:941832. doi: 10.3389/fendo.2022.941832. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387893 Free PMC article. Review.
References
-
- Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38:1669–74. https://doi.org/10.1007/s00259-011-1835-8 . - DOI - PubMed - PMC
-
- Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56. https://doi.org/10.1007/s00259-008-0778-1 . - DOI - PubMed
-
- Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58. https://doi.org/10.2967/jnumed.110.075101 . - DOI - PubMed
-
- Alsadik S, Gnanasegaran G, Chen L, Quigley AM, Mandair D, Toumpanakis C, et al. Single centre retrospective review of outcome of (177) Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors. J Neuroendocrinol. 2022;34: e13210. https://doi.org/10.1111/jne.13210 . - DOI - PubMed
-
- Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42:1955–63. https://doi.org/10.1007/s00259-015-3105-7 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical